Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Payables for 15 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 74.03% to $1.1 million in Q4 2025 year-over-year; TTM through Oct 2025 was $1.1 million, a 74.03% decrease, with the full-year FY2025 number at $400781.0, down 94.3% from a year prior.
  • Payables was $1.1 million for Q4 2025 at PharmaCyte Biotech, up from $465209.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $7.0 million in Q2 2024 to a low of $1983.0 in Q4 2021.
  • A 5-year average of $1.7 million and a median of $475078.5 in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 96.19% in 2022, then soared 138172.69% in 2024.
  • PharmaCyte Biotech's Payables stood at $1983.0 in 2021, then skyrocketed by 43332.98% to $861276.0 in 2022, then skyrocketed by 390.14% to $4.2 million in 2023, then fell by 3.61% to $4.1 million in 2024, then crashed by 74.03% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Payables are $1.1 million (Q4 2025), $465209.0 (Q3 2025), and $400781.0 (Q2 2025).